Regression of neovascular posterior capsule vessels by intravitreal bevacizumab.
We present a 76-year-old woman who developed neovascularization of the posterior capsule 1 year after extracapsular cataract extraction. She had type 2 diabetes for 15 years, with proliferative diabetic retinopathy that had been treated with panretinal photocoagulation. The neovascular vessels on the posterior capsule originated from existing rubeosis iridis and regressed after a single injection of intravitreal bevacizumab (Avastin). The patient's visual acuity increased to 20/40 after an uneventful neodymium:YAG capsulotomy.
Eren
Ebru
E
Department of Ophthalmology, Faculty of Medicine, Başkent University, 06490 Bahçelievler, Ankara, Turkey.
Küçükerdönmez
Cem
C
Yilmaz
Gürsel
G
Akova
Yonca A
YA
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002387:Cataract Extraction; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003930:Diabetic Retinopathy / Q000150:complications / Q000601:surgery; D005260:Female; D006801:Humans; D007267:Injections; D007498:Iris / Q000098:blood supply; D017075:Laser Coagulation; D007903:Lens Capsule, Crystalline / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab